PARP inhibitors are drugs which inhibit the enzyme called poly ADP ribose polymerase (PARP). PARP inhibitors are developed for treating several diseases, the most important one is cancer. Several types of cancers rely on PARP enzymes than regular cells, which makes these inhibitors an effective mode of treating cancers. PARP inhibitors are used to treat a subset of ovarian cancer. Currently, 3 PARP inhibitors have been approved for use in ovarian cancer patients who have undergone 3 or more prior lines of chemotherapy. Olaparib (Lynpraza) was the first PARP inhibitor to receive approval in 2014 followed by Rucaparib in 2016, and Niraparib in 2017. Furthermore, several PARP inhibitors which are currently in later stages of development have shown promising results in recently released clinical trials data.
Market Dynamics
The global PARP inhibitors market is driven by product developments, increasing number of positive results, as well as availability of novel therapies in the market. Companies such as Pfizer, AstraZeneca and Tesaro, Inc. have a robust pipeline of PARP inhibitors and several ongoing trials of products are scheduled to be completed by 2022. These factors are expected to propel growth of the market over the forecast period. However, side effects associated with the drugs and drug resistance among patients are some of the factors that are expected to hamper the market growth.
Key features of the study:
- This report provides in-depth analysis of the global PARP inhibitor market and provides market size (US$ Mn) and compound annual growth rate (CAGR%) for the forecast period (2019–2027), considering 2018 as the base year
- It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
- This study also provides key insights about market drivers, restraints, opportunities, new product launches or approvals, market trends, regional outlook, and competitive strategies adopted by key players
- It profiles key players in the global PARP inhibitor market based on the following parameters – company overview, financial performance, product portfolio, market presence, distribution strategies, key developments, strategies, and future plans
- Key companies covered as a part of this study include AstraZeneca Plc., Johnson & Johnson, GlaxoSmithKline plc., Pfizer, Inc., Clovis Oncology Inc., AbbVie Inc., Bristol - Myers Squibb, Merck KGaA, Genentech, Inc., Repare Therapeutics Inc., Sierra Oncology, Inc., Karyopharm Therapeutics Inc., Ono Pharmaceutical Co., LTD., and Jiangsu Hengrui Medicine Co., Ltd.
- Insights from this report would allow marketers and management authorities of companies to make informed decisions regarding future product launches, technology up-gradation, market expansion, and marketing tactics
- The global PARP inhibitor market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
- Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global PARP inhibitor market
Detailed Segmentation:
- Global PARP inhibitor Market, By Drug Type:
- Niraparib (Zejula)
- Olaparib (Lynparza)
- Rucaparib (Rubraca)
- Talazoparib (Talzenna)
- Global PARP inhibitor Market, By Application:
- Ovarian Cancer
- Breast Cancer
- Global PARP inhibitor Market, By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- Global PARP inhibitor Market, By Region:
- North America
- By Drug Type:
- Niraparib (Zejula)
- Olaparib (Lynparza)
- Rucaparib (Rubraca)
- Talazoparib (Talzenna)
- By Application:
- Ovarian Cancer
- Breast Cancer
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Latin America
- By Drug Type:
- Niraparib (Zejula)
- Olaparib (Lynparza)
- Rucaparib (Rubraca)
- Talazoparib (Talzenna)
- By Application:
- Ovarian Cancer
- Breast Cancer
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Brazil
- Mexico
- Argentina
- Rest of Latin America
- Europe
- By Drug Type:
- Niraparib (Zejula)
- Olaparib (Lynparza)
- Rucaparib (Rubraca)
- Talazoparib (Talzenna)
- By Application:
- Ovarian Cancer
- Breast Cancer
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- Germany
- U.K.
- France
- Italy
- Spain
- Asia Pacific
- By Drug Type:
- Niraparib (Zejula)
- Olaparib (Lynparza)
- Rucaparib (Rubraca)
- Talazoparib (Talzenna)
- By Application:
- Ovarian Cancer
- Breast Cancer
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- China
- India
- Japan
- Australia
- South Korea
- ASEAN
- Rest of Asia Pacific
- Middle East
- By Drug Type:
- Niraparib (Zejula)
- Olaparib (Lynparza)
- Rucaparib (Rubraca)
- Talazoparib (Talzenna)
- By Application:
- Ovarian Cancer
- Breast Cancer
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- GCC
- Israel
- Rest of Middle East
- Africa
- By Drug Type:
- Niraparib (Zejula)
- Olaparib (Lynparza)
- Rucaparib (Rubraca)
- Talazoparib (Talzenna)
- By Application:
- Ovarian Cancer
- Breast Cancer
- By Distribution Channel:
- Hospital Pharmacies
- Retail Pharmacies
- Online Pharmacies
- By Country:
- South Africa
- Central Africa
- North Africa
- Company Profiles
- AstraZeneca Plc.,*
- Company Overview
- Material Portfolio
- Financial Performance
- Key Highlights
- Johnson & Johnson
- GlaxoSmithKline plc.
- Pfizer, Inc.,
- Clovis Oncology Inc.
- AbbVie Inc.
- Bristol - Myers Squibb
- Merck KGaA
- Genentech, Inc.
- Repare Therapeutics Inc.
- Sierra Oncology, Inc.
- Karyopharm Therapeutics Inc.
- Ono Pharmaceutical Co. Ltd.,
- Jiangsu Hengrui Medicine Co., Ltd.
“*” marked represents similar segmentation in other categories in the respective section.
